# Gate Bioscience

> Gate Bioscience is a Brisbane, California biotech building a brand-new class of medicines it calls Molecular Gates: oral small molecules that stop disease-causing proteins from ever leaving the cell. Instead of chasing proteins after they are secreted into the body, Gate's drugs bind Sec61, the single channel every one of the roughly 4,000 human secreted and membrane proteins must pass through, and selectively block a target protein so the cell degrades it. Founded in 2021 and emerged from stealth in 2023 with $60M, the company has raised about $135M total and is pushing its lead programs toward IND-enabling studies and Phase 1 trials.

- **Founded:** 2021
- **Headquarters:** Brisbane, California, United States
- **Founders:** Jordi Mata-Fink (Co-Founder & CEO), Raman Talwar (Co-Founder), Pat Sharp (Co-Founder & Chemistry Lead)
- **Team size:** ~42 employees
- **Products:** Molecular Gates platform, Oral Molecular Gate medicines, Biopharma partnerships
- **Notable:** Invented Molecular Gates, a genuinely new drug class with a novel mechanism of action (blocking Sec61 secretion), Emerged from stealth in 2023 with $60M Series A, Closed a $65M oversubscribed Series B in November 2025, bringing total raised to ~$135M

## Products & services

- **Molecular Gates platform** — A drug discovery engine that designs small molecules binding the Sec61 secretory channel to selectively block a chosen disease-causing protein from exiting the cell, redirecting it for natural degradation.
- **Oral Molecular Gate medicines** — First-in-class, orally available small molecule therapeutics targeting high-value proteins in immunology, inflammation and neuroscience, advancing toward IND-enabling studies and Phase 1 trials.
- **Biopharma partnerships** — B2B collaborations applying Gate's discovery engine to generate selective molecular gates for partners' targets alongside Gate's own pipeline.

## Achievements

- Invented Molecular Gates, a genuinely new drug class with a novel mechanism of action (blocking Sec61 secretion)
- Emerged from stealth in 2023 with $60M Series A
- Closed a $65M oversubscribed Series B in November 2025, bringing total raised to ~$135M
- Attracted Eli Lilly as a strategic investor alongside top-tier life-science VCs
- Built the platform into a repeatable drug discovery engine spanning multiple therapeutic areas

## Latest updates

- **2025-11** — Closed $65M oversubscribed Series B led by Forbion with new investor Eli Lilly; proceeds to advance lead programs through IND-enabling studies and Phase 1 trials. Vanessa Carle of Forbion joined the board.
- **2023-11** — Emerged from stealth and introduced Molecular Gates with $60M Series A led by Versant Ventures and a16z Bio + Health.

## Links

- Website: https://www.gatebio.com
- LinkedIn: https://www.linkedin.com/company/gatebio

---

Profile page: https://yespress.io/gate-bioscience
Published by YesPress — https://yespress.io
Last updated: 2026-06-15